Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28040037 | 0.79 | GAA (0.37) | SMN1; SMN2 | |
| SCHEMBL3344044 | 0.76 | MEN1 (0.33) | OPRM1OPRL1MMP2MMP3MMP9 | |
| SCHEMBL16937436 | 0.74 | LMNA (0.32) | — | |
| SCHEMBL6548185 | 0.73 | KDM1A (0.33) | — | |
| SCHEMBL10640077 | 0.72 | KDM1A (0.32) | — | |
| SCHEMBL28846306 | 0.72 | OPRM1 (0.35) | OPRM1OPRL1MMP2MMP3MMP9 | |
| SCHEMBL30777406 | 0.72 | — | — | |
| SCHEMBL21412875 | 0.72 | — | — | |
| SCHEMBL28485724 | 0.72 | HSD11B1 (0.34) | MMP2MMP3MMP9 | |
| SCHEMBL28628019 | 0.70 | TSHR (0.31) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026398-B2 | Catalysts comprising a combination of oxidized metals and a method for cleaving phenylalkyl hydroperoxides using the catalysts | SHELL OIL COMPANY | 2011-09-27 | — | — | US | disclosed |
| US-20100063326-A1 | CATALYSTS COMPRISING A COMBINATION OF OXIDIZED METALS AND A METHOD FOR CLEAVING PHENYLALKYL HYDROPEROXIDES USING THE CATALYSTS | SHELL OIL COMPANY | 2010-03-11 | — | — | US | disclosed |
| EP-1915357-A1 | 2-HYDROXY-PROPIONIC ACID DERIVATIVES AND 3-HYDROXY-BENZOFURAN-2-ONE DERIVATIVES WITH AFFINITY FOR THE GABA-B-RECEPTOR | F. Hoffmann-Roche AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007137021-A2 | CATALYSTS COMPRISING A COMBINATION OF OXIDIZED METALS AND A METHOD FOR CLEAVING PHENYLALKYL HYDROPEROXIDES USING THE CATALYSTS | SHELL OIL COMPANY (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007014843-A1 | 2-HYDROXY-PROPIONIC ACID DERIVATIVES AND 3-HYDROXY-BENZOFURAN-2-ONE DERIVATIVES WITH AFFINITY FOR THE GABA-B-RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063326-A1 | CATALYSTS COMPRISING A COMBINATION OF OXIDIZED METALS AND A METHOD FOR CLEAVING PHENYLALKYL HYDROPEROXIDES USING THE CATALYSTS | GPX4, SOD1, PPOX | OPRM1 1401/4885OPRL1 3122/4885MMP2 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.